Literature DB >> 35992019

Drug Diffusion Through Peer Networks: The Influence of Industry Payments.

Leila Agha1, Dan Zeltzer2.   

Abstract

Pharmaceutical companies market to physicians through individual detailing accompanied by monetary or in-kind transfers. Large compensation payments to a small number of physicians account for most of this promotional spending. Studying US promotional payments and prescriptions for anticoagulant drugs, we investigate how peer influence broadens the payments' reach. Following a compensation payment, prescriptions for the marketed drug increase by both the paid physician and the paid physician's peers. Payments increase prescriptions to both recommended and contraindicated patients. Over three years, marketed anticoagulant prescriptions rose 23 percent due to payments, with peer spillovers contributing a quarter of the increase.

Entities:  

Keywords:  I11; L14; O33; health care; networks; peer effects; pharmaceutical advertising; technology diffusion

Year:  2022        PMID: 35992019      PMCID: PMC9387671          DOI: 10.1257/pol.20200044

Source DB:  PubMed          Journal:  Am Econ J Econ Policy        ISSN: 1945-774X


  16 in total

1.  Medicare's Part D Drug Benefit At 10 Years: Firmly Established But Still Evolving.

Authors:  John F Hoadley; Juliette Cubanski; Patricia Neuman
Journal:  Health Aff (Millwood)       Date:  2015-10       Impact factor: 6.301

2.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Authors:  Ron Pisters; Deirdre A Lane; Robby Nieuwlaat; Cees B de Vos; Harry J G M Crijns; Gregory Y H Lip
Journal:  Chest       Date:  2010-03-18       Impact factor: 9.410

3.  Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.

Authors:  Colette DeJong; Thomas Aguilar; Chien-Wen Tseng; Grace A Lin; W John Boscardin; R Adams Dudley
Journal:  JAMA Intern Med       Date:  2016-08-01       Impact factor: 21.873

4.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.

Authors:  Gregory Y H Lip; Lars Frison; Jonathan L Halperin; Deirdre A Lane
Journal:  J Am Coll Cardiol       Date:  2010-11-24       Impact factor: 24.094

5.  THE LOCAL INFLUENCE OF PIONEER INVESTIGATORS ON TECHNOLOGY ADOPTION: EVIDENCE FROM NEW CANCER DRUGS.

Authors:  Leila Agha; David Molitor
Journal:  Rev Econ Stat       Date:  2018-03-02

6.  Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.

Authors:  Brian F Gage; Carl van Walraven; Lesly Pearce; Robert G Hart; Peter J Koudstaal; B S P Boode; Palle Petersen
Journal:  Circulation       Date:  2004-10-11       Impact factor: 29.690

7.  Medical Marketing in the United States, 1997-2016.

Authors:  Lisa M Schwartz; Steven Woloshin
Journal:  JAMA       Date:  2019-01-01       Impact factor: 56.272

8.  Types and Distribution of Payments From Industry to Physicians in 2015.

Authors:  Kathryn R Tringale; Deborah Marshall; Tim K Mackey; Michael Connor; James D Murphy; Jona A Hattangadi-Gluth
Journal:  JAMA       Date:  2017-05-02       Impact factor: 56.272

9.  Association Between Academic Medical Center Pharmaceutical Detailing Policies and Physician Prescribing.

Authors:  Ian Larkin; Desmond Ang; Jonathan Steinhart; Matthew Chao; Mark Patterson; Sunita Sah; Tina Wu; Michael Schoenbaum; David Hutchins; Troyen Brennan; George Loewenstein
Journal:  JAMA       Date:  2017-05-02       Impact factor: 56.272

Review 10.  New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events.

Authors:  Ymer H Mekaj; Agon Y Mekaj; Shkelzen B Duci; Ermira I Miftari
Journal:  Ther Clin Risk Manag       Date:  2015-06-24       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.